Mainstream

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase

Post ContentexelRead More

You might also be interested in reading OPNX, the Exchange Built by Founders of Doomed Hedge Fund Three Arrows, Is Shutting Down.

July 29, 2025
In Mainstream